darusentan
Sign in to saveAlso known as HMR-4005, LU-135252
Darusentan (LU-135252; HMR-4005) is an endothelin receptor antagonist. Gilead Colorado, a subsidiary of Gilead Sciences, under license from Abbott Laboratories, is developing darusentan for the potential treatment of uncontrolled hypertension.
Research
205 papers- Darusentan, a selective endothelin A receptor antagonist, for the oral treatment of resistant hypertension.Therapeutic advances in cardiovascular disease · 2010
- Darusentan: a new perspective for treatment of resistant hypertension?Expert opinion on investigational drugs · 2008
- Efficacy of pharmacological and interventional treatment for resistant hypertension: a network meta-analysis.Cardiovascular research · 2024
- Darusentan (Abbott Laboratories).IDrugs : the investigational drugs journal · 2001
- Darusentan is a potent inhibitor of endothelin signaling and function in both large and small arteries.Canadian journal of physiology and pharmacology · 2010
via PubMed
Wikidata facts
- Mass
- 410.147786
Show 4 more facts
- chemical formula
- C₂₂H₂₂N₂O₆
- isomeric SMILES
- COC1=CC(=NC(=N1)O[C@H](C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC)OC
- canonical SMILES
- COC1=CC(=NC(=N1)OC(C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC)OC
- Commons category
- Darusentan
Sources (2)
via Wikidata · CC0
~1 min read
Article
2 sectionsContents
- See also
- References
Darusentan (LU-135252; HMR-4005) is an endothelin receptor antagonist. Gilead Colorado, a subsidiary of Gilead Sciences, under license from Abbott Laboratories, is developing darusentan for the potential treatment of uncontrolled hypertension.
In June 2003, Myogen licensed the compound from Abbott for its application in the cancer field.
Connections
liver
Entity
medication
Entity
circulatory system
Entity
arterial hypertension
Entity
digital object identifier
Entity
chemical formula
Entity
molar mass
Entity
Q180686
Entity
CAS Registry Number
Entity
PubChem
Entity
Anatomical Therapeutic Chemical Classification System
Entity
pharmacokinetics
Entity
simplified molecular input line entry specification
Entity
Q2311683
Entity
IUPAC nomenclature of chemistry
Entity
immunotherapy
Entity
Q22908627
Entity
biological half-life
Entity
Abbott Laboratories
Company
route of administration
Entity
Categories
Aromatic ethersCarboxylic acidsChemical pages without DrugBank identifierDiphenylmethanol ethersDrugboxes which contain changes to verified fieldsDrugboxes which contain changes to watched fieldsDrugs not assigned an ATC codeDrugs with non-standard legal statusECHA InfoCard ID from WikidataEndothelin receptor antagonistsExperimental drugsLactims